BCM
AKRO

BlueCrest Capital Management’s Akero Therapeutics AKRO Stock Holding History

BlueCrest Capital Management’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-17,000
Closed -$326K – 578
2019
Q2 		$326K Buy
+17,000
New +$322K 0.02% 267

Other funds holding AKRO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BlueCrest Capital Management's AKRO Position: Q3 2019 in Review

BlueCrest Capital Management sold out of Akero Therapeutics (AKRO) in Q3 2019, closing a stake of 17,000 shares — an estimated $326K sold.

BlueCrest Capital Management first reported a position in AKRO in Q2 2019 and held it in 1 quarter. The position peaked at $326K in Q2 2019. 54 funds tracked by Wall St. Rank hold AKRO as of Q3 2019.

  • BlueCrest Capital Management reported no remaining Akero Therapeutics position as of Q3 2019 after selling out during the quarter.
  • BlueCrest Capital Management sold 17,000 Akero Therapeutics shares in Q3 2019, an estimated $326K.
  • BlueCrest Capital Management first reported a position in Akero Therapeutics in Q2 2019 and held it in 1 quarter.
  • BlueCrest Capital Management's Akero Therapeutics position peaked at $326K in Q2 2019.
  • 54 funds tracked by Wall St. Rank held Akero Therapeutics as of Q3 2019.

Based on BlueCrest Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.